TP53 and B-cell chronic lymphocytic leukemia: However, in the current treatment era, with novel agents ibrutinib, idelalisib and BCL2 antagonists demonstrating activity in patients with high-risk CLL [7••, 69•], including those with del 17p and p53 mutations, these guidelines are being questioned and were recently reviewed in the light of this shifting landscape [69•].